Andrew Kuykendall, MD, is an assistant member of the Department of Malignant Hematology and clinical researcher at Moffitt Cancer Center in Tampa, Fla. He focuses on developing novel, disease-modifying therapies for patients with myeloproliferative neoplasms. He is an active collaborator nationally and internationally and serves on the National Comprehensive Cancer Network (NCCN) Guidelines Panel for myeloproliferative neoplasms, systemic mastocytosis, and myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes. He is the primary investigator on numerous clinical trials for patients with myelofibrosis and is an active member of the Myeloproliferative Neoplasms — Research Consortium.
He earned his medical degree at the University of Florida in Gainesville, Fla. and completed his internal medicine residency and hematology/oncology fellowships at the University of South Florida and Moffitt Cancer Center in Tampa.